Compare Barclays PLC (BCS) vs Zoetis Inc (ZTS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Barclays PLC vs Zoetis Inc — how do they compare? Barclays PLC trades at $28 (market cap $93.87B), while Zoetis Inc trades at $72.41 (market cap $31.14B). The key difference: Barclays PLC is far larger — about 3× Zoetis Inc's market cap, and Zoetis Inc pays the higher dividend (2.81%). Which is the better fit depends on your goals.
| BCS | ZTS | |
|---|---|---|
Market Cap | $93.87B | $31.14B |
Sector | Financials | Health |
52-Week High | $28.56 | $156.76 |
52-Week Low | $19.36 | $71.91 |
Dividend Yield | 2.19% | 2.81% |
Enterprise Value | — | $38.70B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Barclays PLC (BCS) trades at $27.98, up 0.18% today, with a bullish technical signal from moving averages and neutral oscillators. The stock shows strong fundamentals, including a P/E of 10.68, P/B of 0.88, and net income margin of 25.51%, with Q2 2026 EPS beating estimates at $0.90. Recent news highlights a 17% profit jump in H1 2026 but also a securities class action investigation, creating mixed sentiment.
The outlook is cautiously optimistic, supported by earnings beats and a 68% analyst buy rating, but risks include cost pressures, legal scrutiny, and market volatility. Upside potential hinges on sustained profit growth and efficient cost management amid economic uncertainties.
Zoetis (ZTS) trades at $74.86, up 3.03% today but facing bearish technical signals with 16 sell indicators. The company reported mixed Q2 2026 results, beating EPS estimates but missing revenue expectations, while cutting full-year guidance due to softer pet healthcare demand. Strong fundamentals include a 27.69% net margin and 64.91% ROE, though valuation metrics show a P/E of 12.29 and P/S of 3.41.
The stock presents a value opportunity with analyst consensus target of $94.90 (27% upside), but faces near-term headwinds from competitive pressures and class action lawsuits. Investors should weigh strong profitability against slowing growth in companion animal segments and technical bearishness.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Barclays PLC
Barclays is a universal bank headquartered in the United Kingdom. It operates via two principal segments
Read more on BCS →About Zoetis Inc
Zoetis sells anti-infectives, vaccines, parasiticides, diagnostics, and other health products for animals. The firm earns slightly less than half of total revenue from production animals (cattle, pigs, poultry, and so on), and more than half from companion animal (dogs, horses, cats) products make up the other half. Its U.S. business is heavily skewed toward companion animals, while its international business is slightly skewed toward production animals. The firm has the largest market share in the industry and was previously Pfizer's animal health unit.
Read more on ZTS →
